Literature DB >> 18602081

Progression and timing of treatment of zone I retinopathy of prematurity.

Yuka Soh1, Takahiro Fujino, Yoshikazu Hatsukawa.   

Abstract

PURPOSE: To clarify the progression of zone I retinopathy of prematurity (ROP) and elucidate the most suitable time and method of treatment.
DESIGN: Interventional case series.
METHODS: Forty-six eyes of 23 zone I ROP infants were studied at a single institution. Birth weight ranged from 448 to 954 g, and gestational age ranged from 22 to 26 weeks. Fundus examination was started at 29 or 30 weeks postmenstrual age and was performed once or more per week. The first treatment was performed using laser photocoagulation or cryotherapy when zone I ROP progressed to the following criteria. Treatment criteria A included 35 eyes of 18 cases of zone I any stage ROP with plus disease (Early Treatment for Retinopathy of Prematurity [ETROP] type 1), criteria B included five eyes of three cases of zone I stage 3 ROP with or without plus disease (ETROP type 1), criteria C included six eyes of four cases of stage 1 or stage 2 ROP without plus disease; the demarcation lines belonged, in large part, within the zone I area.
RESULTS: Hazy media such as corneal opacity, miotic pupil, tunica vasculosa lentis, and hazy vitreous persisted until approximately 32 weeks postmenstrual age. The mean period between stage 1 and stage 3 mild was one week, that between stage 1 and stage 3 moderate was 1.7 weeks, and that between stage 1 and stage 3 severe was 1.3 weeks. The period between stage 1 and the first treatment was zero to 20 days, and 60.9% of all the cases were treated within 10 days after stage 1. Six of 46 eyes had unfavorable outcomes. Surgical results of our treatment were comparable or better than those of other reports.
CONCLUSIONS: Immediate treatment was required when zone I ROP was diagnosed behind persistent hazy media.

Entities:  

Mesh:

Year:  2008        PMID: 18602081     DOI: 10.1016/j.ajo.2008.05.010

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.

Authors:  Huseyin Yetik; Murat Gunay; Sarkis Sirop; Ziya Salihoglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-14       Impact factor: 3.117

2.  Alterations of the tunica vasculosa lentis in the rat model of retinopathy of prematurity.

Authors:  Tara L Favazza; Naoyuki Tanimoto; Robert J Munro; Susanne C Beck; Marina Garcia Garrido; Christina Seide; Vithiyanjali Sothilingam; Ronald M Hansen; Anne B Fulton; Mathias W Seeliger; James D Akula
Journal:  Doc Ophthalmol       Date:  2013-06-08       Impact factor: 2.379

Review 3.  The progress of prophylactic treatment in retinopathy of prematurity.

Authors:  Hong-Bing Zhang; Xiao-Dong Wang; Kun Xu; Xiao-Gang Li
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

4.  Refractive Development in the "ROP Rat".

Authors:  Toco Y P Chui; David Bissig; Bruce A Berkowitz; James D Akula
Journal:  J Ophthalmol       Date:  2012-02-08       Impact factor: 1.909

5.  Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity.

Authors:  Shumpei Obata; Tomoaki Higashiyama; Taku Imamura; Masashi Kakinoki; Takahide Yanagi; Yoshihiro Maruo; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2019-12-10

6.  Modeling absolute zone size in retinopathy of prematurity in relation to axial length.

Authors:  Sean K Wang; Edward Korot; Moosa Zaidi; Marco H Ji; Ahmad Al-Moujahed; Natalia F Callaway; Jochen Kumm; Darius M Moshfeghi
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.